Neuralstem in the News

 

  • Neuralstem’s Pipeline Addresses Enormous Unmet Medical Needs

By Jason Napodano, CFA, PropThink, August 12, 2013

A comprehensive overview of Neuralstem’s NSI-566 cell therapy clinical trials for unmet medical needs – ALS, spinal cord injury, and ischemic stroke – as well as Neuralstem’s novel small molecule drug, NSI-189, nearing the conclusion of its Phase Ib trial in major depressive disorder, expected in the second half of 2013, is the focus of this to-the-minute article.

View Article

  • ALS patient improving with stem-cell treatments

By Jeff Dore, WSB-TV Atlanta, August 1, 2013

Jeff Dore visits NSI-566/ALS Phase I patient Ted Harada, who shares his story, claiming he's "the luckiest man on the face of the earth." Site Principal Investigator, Emory's Jonathan D. Glass, MD, is also interviewed, in advance of the Phase II trial.

View Segment

  • U-M stem cell trial produces positive results for ALS patients

By Kim Kozlowski, The Detroit News, July 8, 2013

“The results suggest that [NSI-566] intraspinal stem cell transplantation of ALS subjects with no bulbar symptoms early in the course of their disease could slow disease progression,” Feldman said. “I am extremely hopeful that we have found a way early in the course of the disease to make a true difference. Any treatment that can slow the progression of the disease is truly a home run for Lou Gehrig.” ALS trial principal investigator, Dr. Eva Feldman, is quoted in this front-page feature story exploring Phase I results and the upcoming NSI-566/ALS Phase II trial planned this year, which will increase dosage and number of injections.

View Article

  • Human Stem Cells Help Acute SCI Rats; Chronic Trial Update

By Sam Maddox, Christopher & Dana Reeve Foundation, May 31, 2013

Neuralstem’s Chairman of the Board and Chief Scientific Officer, Karl Johe, Ph.D., shared insights on the breakthrough scientific research that led to the FDA approval of the upcoming NSI-566/chronic spinal cord injury trial with Christopher & Dana Reeve Foundation’s blogger, Sam Maddox. Mr. Maddox also identified the five planned trial centers.

View Article

  • FDA-approved Stem Cell Trial Dramatically Slows ALS

By Cynthia Fox, Bioscience Technology, May 30, 2013

“Being a Michigan wolverine, I’ll use an analogy. It’s [no significant disease progression] as rare as a red wolf. And that is very rare,” says NSI-566/ALS clinical trial Principal Investigator Dr. Eva Feldman. Dr. Feldman and Neuralstem’s President and CEO Richard Garr are interviewed for this feature story that explores the new ALS Phase I data from six of the extraordinary responders, after Dr. Feldman presented it at the Romanian Neurological Society Congress earlier in May.

View Article

Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.

Privacy and Terms ©Neuralstem, Inc. 2014

Crain’s Detroit Business explores NSI-566 next steps with ALS P.I., Dr. Eva Feldman, and reviews additional indication, Alzheimer’s disease, following promising animal research. | 8.1.14
The Wall Street Journal interviews President/CEO, Richard Garr, on patient-directed social media’s impact on trials. NSI-566/ALS patients have independently chosen to blog online. | 7.30.14
FORBES' feature quotes President/CEO Richard Garr extensively, on the differentiation and commercialization of Neuralstem’s proprietary cell technology. | November 2013
FOX Medical Team's Beth Galvin continues her NSI-566/ALS coverage at Emory with a patient’s perspective segment. Phase I patients, Ted Harada and John Conley, are featured. | 11.20.13
Bethesda Magazine feature provides rich insights on Neuralstem’s “potential wonder drug aimed specifically at rebuilding the hippocampus”: NSI-189. | November-December 2013
Practical Neurology interviews Chairman and CSO Dr. Karl Johe and P.I. Dr. Eva Feldman about the NSI-566/ALS trials in “Decreasing Progression, Increasing Function.” | October 2013
FOX News Detroit walks with NSI-566/ALS Phase I patient Ted Harada and P.I. Dr. Eva Feldman on the eve of the Phase II trial. | 8.28.13
Bioscience Technology ALS P.I. Dr. Eva Feldman and Neuralstem’s President/CEO Richard Garr in a feature that explores data from six extraordinary ALS responders – “as rare as a red wolf.” | 5.30.13
MIT's Technology Review reports on CELL SCI research showing “paralyzed rats walk again after stem cell transplant” of NSI-566, suggesting hope for treatment of spinal cord injury. | 9.13.12